Quick Answer
Indivior Pharmaceuticals, Inc. reported Diluted EPS of $1.64 per share for fiscal year 2025.
Indivior Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $1.64 | +3180.0% |
| 2024 | $0.05 | +105.4% |
| 2023 | -$0.92 | -187.5% |
| 2022 | -$0.32 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.33 | +106.2% | +135.7% |
| June 30, 2025 | $0.14 | +119.4% | -63.2% |
| March 31, 2025 | $0.38 | -15.6% | +137.5% |
| September 30, 2024 | $0.16 | — | +122.2% |
| June 30, 2024 | -$0.72 | — | -260.0% |
| March 31, 2024 | $0.45 | — | — |
- Indivior Pharmaceuticals, Inc. showed an increase of +3180.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Indivior Pharmaceuticals, Inc.’s diluted eps has grown by 612.5% (from $0.32 per share (loss) to $1.64 per share).
- The most recent figure is from Indivior Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: